MCRB Seres Therapeutics
- 1.110
- -0.080-6.72%
- 1.110
- 0.0000.00%
Seres Therapeutics News
Seres Therapeutics | 8-K: Current report
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Dere Willard H
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Fraser Claire
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Biondi Paul
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Kender Richard N
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Graves Kurt
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ausiello Dennis A
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Berenson Stephen
Seres Therapeutics | 8-K: Current report
Seres Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(4.5%)
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Thorell Marella
Seres Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Thorell Marella
Seres Therapeutics | DEF 14A: Definitive information statements
Seres Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Seres Therapeutics | 10-K: Annual report
Seres Therapeutics | 8-K: Current report
Seres Therapeutics | 8-K: Current report
Seres Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer DesRosier Thomas
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Shaff Eric D.
Analysis
Price Target
No Data
